MX366949B - Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. - Google Patents
Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.Info
- Publication number
- MX366949B MX366949B MX2015018032A MX2015018032A MX366949B MX 366949 B MX366949 B MX 366949B MX 2015018032 A MX2015018032 A MX 2015018032A MX 2015018032 A MX2015018032 A MX 2015018032A MX 366949 B MX366949 B MX 366949B
- Authority
- MX
- Mexico
- Prior art keywords
- histone demethylase
- compounds
- agent known
- phenylethylidene
- substituted
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title abstract 4
- 108010074870 Histone Demethylases Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- HAUVWRQIVOPGOE-FOWTUZBSSA-N n-[(e)-1-phenylethylideneamino]benzamide Chemical class C=1C=CC=CC=1C(/C)=N/NC(=O)C1=CC=CC=C1 HAUVWRQIVOPGOE-FOWTUZBSSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 abstract 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 abstract 1
- YIFUEAQAGQHWJW-UHFFFAOYSA-N [3-(5-chloro-2-hydroxyphenyl)-4-methylpyrazol-1-yl]-(3-morpholin-4-ylsulfonylphenyl)methanone Chemical class CC1=CN(C(=O)C=2C=C(C=CC=2)S(=O)(=O)N2CCOCC2)N=C1C1=CC(Cl)=CC=C1O YIFUEAQAGQHWJW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/921,895 US9266838B2 (en) | 2011-08-15 | 2013-06-19 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| PCT/US2014/043179 WO2014205213A1 (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015018032A MX2015018032A (es) | 2016-10-03 |
| MX366949B true MX366949B (es) | 2019-07-30 |
Family
ID=52105283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015018032A MX366949B (es) | 2013-06-19 | 2014-06-19 | Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3010915B1 (enExample) |
| JP (1) | JP6525162B2 (enExample) |
| KR (1) | KR102288648B1 (enExample) |
| CN (2) | CN105555784B (enExample) |
| AU (1) | AU2014281398B2 (enExample) |
| BR (1) | BR112015032113B1 (enExample) |
| CA (1) | CA2915817C (enExample) |
| ES (1) | ES2739814T3 (enExample) |
| IL (1) | IL243200B (enExample) |
| MX (1) | MX366949B (enExample) |
| NZ (1) | NZ715331A (enExample) |
| SG (2) | SG11201510376QA (enExample) |
| WO (1) | WO2014205213A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102288648B1 (ko) * | 2013-06-19 | 2021-08-12 | 유니버시티 오브 유타 리서치 파운데이션 | 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| NZ723203A (en) | 2014-02-13 | 2020-08-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016119031A1 (pt) * | 2015-01-29 | 2016-08-04 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Ｌｓｄ１阻害剤の塩 |
| BR112018013074A2 (en) | 2015-12-30 | 2018-12-11 | Novartis Ag | immune effector cell therapies with enhanced efficacy |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| CN108727377A (zh) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 |
| SI3661510T1 (sl) | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Postopki zdravljenja vedenjskih sprememb |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| CN108689960B (zh) * | 2018-06-07 | 2022-03-04 | 济南大学 | 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| US20220151998A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| CN111471096B (zh) * | 2020-01-15 | 2022-02-18 | 上海众启生物科技有限公司 | 用于阿尔茨海默症自身抗体检测的含有adarb1蛋白片段组合物 |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN116444437B (zh) * | 2023-03-08 | 2025-09-16 | 曲靖师范学院 | 抗癌医药达洛鲁胺的合成方法 |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025188857A1 (en) * | 2024-03-05 | 2025-09-12 | University Of Florida Research Foundation, Incorporated | Hdac8 degraders and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005324024B2 (en) * | 2005-01-07 | 2011-02-17 | F. Hoffmann-La Roche Ag | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| WO2006136008A1 (en) * | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| US20080214495A1 (en) * | 2005-07-08 | 2008-09-04 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| WO2010083310A2 (en) * | 2009-01-14 | 2010-07-22 | Dow Agrosciences Llc | Fungicidal compositions including hydrazone derivatives and copper |
| US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| US20110189306A1 (en) * | 2010-01-13 | 2011-08-04 | Norbert Kartner | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
| EP2638018A1 (en) * | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| SG2014009609A (en) * | 2011-08-15 | 2014-05-29 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| KR102288648B1 (ko) * | 2013-06-19 | 2021-08-12 | 유니버시티 오브 유타 리서치 파운데이션 | 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체 |
-
2014
- 2014-06-19 KR KR1020167001538A patent/KR102288648B1/ko not_active Expired - Fee Related
- 2014-06-19 CN CN201480045891.0A patent/CN105555784B/zh not_active Expired - Fee Related
- 2014-06-19 CN CN201910116764.XA patent/CN110015984A/zh active Pending
- 2014-06-19 BR BR112015032113-5A patent/BR112015032113B1/pt not_active IP Right Cessation
- 2014-06-19 MX MX2015018032A patent/MX366949B/es active IP Right Grant
- 2014-06-19 JP JP2016521574A patent/JP6525162B2/ja not_active Expired - Fee Related
- 2014-06-19 ES ES14813387T patent/ES2739814T3/es active Active
- 2014-06-19 WO PCT/US2014/043179 patent/WO2014205213A1/en not_active Ceased
- 2014-06-19 SG SG11201510376QA patent/SG11201510376QA/en unknown
- 2014-06-19 NZ NZ71533114A patent/NZ715331A/en not_active IP Right Cessation
- 2014-06-19 AU AU2014281398A patent/AU2014281398B2/en not_active Ceased
- 2014-06-19 EP EP14813387.9A patent/EP3010915B1/en not_active Not-in-force
- 2014-06-19 SG SG10201710543PA patent/SG10201710543PA/en unknown
- 2014-06-19 CA CA2915817A patent/CA2915817C/en active Active
-
2015
- 2015-12-17 IL IL243200A patent/IL243200B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014205213A1 (en) | 2014-12-24 |
| EP3010915B1 (en) | 2019-05-08 |
| NZ715331A (en) | 2019-09-27 |
| JP2016523256A (ja) | 2016-08-08 |
| EP3010915A1 (en) | 2016-04-27 |
| CA2915817A1 (en) | 2014-12-24 |
| MX2015018032A (es) | 2016-10-03 |
| IL243200B (en) | 2020-10-29 |
| KR20160024929A (ko) | 2016-03-07 |
| CN105555784B (zh) | 2019-03-15 |
| AU2014281398B2 (en) | 2018-10-04 |
| KR102288648B1 (ko) | 2021-08-12 |
| IL243200A0 (en) | 2016-02-29 |
| AU2014281398A1 (en) | 2016-01-21 |
| SG11201510376QA (en) | 2016-01-28 |
| EP3010915A4 (en) | 2016-12-28 |
| CA2915817C (en) | 2022-12-13 |
| CN105555784A (zh) | 2016-05-04 |
| JP6525162B2 (ja) | 2019-06-05 |
| BR112015032113A2 (pt) | 2017-03-21 |
| CN110015984A (zh) | 2019-07-16 |
| ES2739814T3 (es) | 2020-02-04 |
| BR112015032113B1 (pt) | 2019-01-29 |
| SG10201710543PA (en) | 2018-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015018032A (es) | Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. | |
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| MY199409A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| PH12015502116A1 (en) | Biaryl amide compounds as kinase inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2017010735A (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX389825B (es) | Compuestos y composiciones para tratar trastornos hematologicos. | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MX2016004703A (es) | Forma salina de hidrocloruro para la inhibicion de ezh2. | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| NZ711424A (en) | Pyridine derivatives as soft rock inhibitors | |
| CL2015002814A1 (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| IL263004B (en) | A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide | |
| MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| CO2018001383A2 (es) | Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp” |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |